Jeffrey Nau - Sep 1, 2021 Form 4 Insider Report for Oyster Point Pharma, Inc. (OYST)

Role
President and CEO, Director
Signature
/s/ Brandon Fenn, Attorney-in-Fact
Stock symbol
OYST
Transactions as of
Sep 1, 2021
Transactions value $
$10,200
Form type
4
Date filed
9/1/2021, 06:00 PM
Next filing
Oct 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OYST Common Stock Options Exercise $10.2K +10K +19.65% $1.02* 60.9K Sep 1, 2021 Direct
holding OYST Common Stock 1K Sep 1, 2021 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OYST Employee Stock Option (Right to Buy) Options Exercise $0 -10K -2.02% $0.00 485K Sep 1, 2021 Common Stock 10K $1.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by the Reporting Person's spouse.
F2 This option was granted on November 10, 2017 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One forty-eighth of the total number of shares subject to the original option vested on December 1, 2017, and one forty-eighth of the remaining shares vested, and continue to vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances.